Leading Australian advisor to the Digital Economy, with a consistent track record of outstanding deal outcomes, including repeat transactions for many of our clients
Latimer Partners is consistently one of Australia's most active corporate advisors to growth-stage companies. Our clients typically generate between $10 million and $200 million in revenue. We bring deep sector knowledge and direct relationships with the most active global and local acquirers. Our track record reflects consistently premium outcomes in a market being reshaped by AI, data regulation, and platform consolidation.
Australia's health-technology sector sits at the intersection of robust healthcare industry macro tailwinds and a dynamic tech ecosystem. It benefits from the defensive characteristics of the healthcare industry as well as the upside from technology's potential to transform care. Private capital interest remains high supported by capital availability and investment needs to digitise the healthcare sector.
The pandemic catalysed a shift to digital healthcare with telehealth, electronic health records (EHRs) and remote patient monitoring moving into the mainstream. Larger healthcare players are acquiring telehealth services and health-IT providers to improve their digital offerings and provide better patient care.
The Australian government has actively supported digital health initiatives from funding telehealth to developing a 10-year National Digital Health Strategy. A stable regulatory environment and pro-innovation policies have increased confidence and provided a favourable backdrop to increased M&A activity in the sector.
The health-tech space in Australia remains fragmented with several start-ups and niche providers targeting specific pain points in the value chain. This presents significant opportunities for consolidation leading to roll-up strategies being deployed to build scale — for example, diagnostic imaging centres and GP practice management software.
Electronic health records are creating increased demand for integrations. Platforms which provide interoperability and seamless administrative workflows across public and private healthcare settings are prime acquisition targets for both domestic and international buyers.
There has been an increased focus on tech adoption that improves patient experience — including appointment apps, online pharmacies, and mental health platforms. This "consumerisation of healthcare" has led to many traditional healthcare companies acquiring start-ups that provide digital solutions which improve patient engagement, outcomes and satisfaction.
Rapid progress in AI, data analytics and medical devices has driven the rise of several start-ups in areas such as AI-enabled imaging, health data analytics, and agentic AI-based clinical tools. As these companies continue to scale, they are likely to become prime capability targets for larger healthcare players and private equity funds.
Whilst the NDIS remains a structurally interesting sector given government-backed demand, demographic tailwinds and fragmentation, the ongoing reforms through 2026 continue to create regulatory uncertainty and compliance burden. As a result, the era of pricing tailwinds and unconstrained growth is likely over. Players who can build scaled, technology-enabled platforms with strong compliance and diversified service lines are likely to emerge as winners and attract premium valuations.
Understanding what acquirers pay premiums for, and why, is central to how we advise clients on timing, positioning, and process design.
Focused on building scalable B2B health-tech platforms via roll-up strategies with a preference for EBITDA-positive or near-positive assets. Targets have included practice management, workforce optimisation, and revenue cycle management software platforms. Pacific Equity Partners, Advent Partners, TPG, and TA Associates have been active in the sector.
Established medtech players have shown interest in acquiring validated Australian device IP or new technology assets that can be sold through their distribution channels. Similarly, global pharma companies are interested in integrating digital therapeutics and companion diagnostics into their pipelines. Examples include ResMed, Cochlear and others.
Sonic Healthcare and Ramsay Healthcare have been investing in and embedding AI platforms across their existing clinical networks. Private health insurers (Medibank, Bupa) and other strategics such as Telstra have been acquiring digital engagement, prevention and analytics capabilities.
Australian super funds have been making co-investments in growth-stage health-tech companies. The National Reconstruction Fund (NRF) has been providing equity to strategic Australian health IP. There is a preference to participate in large syndicated rounds rather than taking control positions.
Latimer Partners focuses exclusively on the digital economy — across software, fintech, healthtech, IT services, and digital media. We understand the operating metrics, growth levers, and buyer expectations that drive value in each sub-sector. This means sharper pre-process positioning, better-prepared management teams, and consistently stronger deal outcomes.
Direct, active relationships with the private equity firms, global strategic acquirers, and domestic buyers most active across the digital economy. We know who is acquiring, what they value, and at what multiples — relationships built over multiple transactions, not cold introductions made at the start of a process.
Latimer Partners is the exclusive Australian affiliate of Arma Partners — one of the world's leading technology M&A advisory firms, with offices across Europe and North America. In 2024, Arma advised on 32 transactions valued at US$58 billion. In a sector where cross-border transactions regularly produce the best outcomes, this international reach is a material advantage.
Since January 2021, Latimer Partners has completed 37 technology transactions. 34% are cross-border. 50% are for repeat clients. Every engagement is 100% referenceable. We do not take mandates we cannot resource properly, and we are selective about the businesses we work with.
Whether you're exploring a sale, acquiring, considering strategic options, or seeking growth capital, we'd welcome a confidential conversation.